Ranitidine Market Withdrawal

On April 1, the FDA requested the immediate withdrawal of all prescription and OTC ranitidine drugs due to NDMA contamination. NDMA levels in some ranitidine products has been found to increase with time and when stored at higher than room temperature, exposing consumers to unacceptable levels of NDMA.

Ranitidine products which includes tablets, capsules, and liquids will not be available to use for new or refills of prescriptions or OTC use. The table below provides a list of alternative therapies on the CareOregon formularies.

 

Medicaid

CareOregon Advantage (Medicare)

H2-receptor antagonists

Famotidine

  • 10mg, 20mg tablet
  • 40mg/5ml suspension covered for age 12 and younger

Cimetidine

  • 200mg, 300mg, 400mg, 800mg tablet
  • 300mg/5ml suspension covered for age 12 and younger

Famotidine

  • 10mg, 20mg tablet
  • 40mg/5ml suspension covered for age 12 and younger

Cimetidine

  • 200mg, 300mg, 400mg 800mg tablet
  • 300mg/5ml suspension

Proton Pump Inhibitors

Omeprazole

  • 10mg, 20mg, 40mg DR capsule
  • 20mg ODT
  • First omeprazole 2mg/ml suspension covered for age 12 and younger
Pantoprazole 20mg, 40mg DR tablet 

 

Omeprazole

  • 10mg, 20mg, 40mg DR capsule

Pantoprazole 20mg, 40mg DR tablet

Lansoprazole

  • 15mg, 30mg DR capsule
  • 15mg, 30mg ODT (PA Required)

Esomeprazole 20mg, 40mg DR capsule (ST Required)

Rabeprazole 20mg tablet


CareOregon has notified members who are affected by the withdrawal. This notice provides information about the withdrawal, alternatives available, and steps to dispose of the drug.

If you have questions about the withdrawal, call us at 503-416-4100 or 800-224-4840, Monday-Friday, 8 a.m. – 5 p.m. Option 3 for Provider, then Option 2 for Pharmacy Staff. After business hours, call 866-325-7344.